Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (211-220 of 232) with videos related to

Pageof 24
Sort By:
Leukemia|October 6, 2019
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasmAnna B Halpern, Nicholas P Howard, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Ejhaem|December 18, 2024
Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG reportJasmine Naru, Megan Othus, ChenWei Lin, et al.
Blood|June 1, 2026
[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene TherapyStefan Radtke, George S Laszlo, Kyle Swing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian CancerYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Pageof 24

Showing results (211-220 of 232) with videos related to

Sort By:
Pageof 24
Leukemia|October 6, 2019
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasmAnna B Halpern, Nicholas P Howard, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.
Biomarker Research|August 21, 2020
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG reportEra L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, et al.
Ejhaem|December 18, 2024
Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG reportJasmine Naru, Megan Othus, ChenWei Lin, et al.
Blood|June 1, 2026
[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene TherapyStefan Radtke, George S Laszlo, Kyle Swing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian CancerYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Pageof 24